For Ewing sarcoma (ES), BCL-2 and BCL-XL are simultaneously required to maintain cell survival, and monotherapy with venetoclax is not sufficient to sensitize ES cells to olaparib. This evidence concerns the gene BCL2 and Ewing sarcoma.